Literature DB >> 8473762

Septic shock in critically ill patients: aetiology, management and outcome.

N S Dahmash1, N H Chowdhury, D F Fayed.   

Abstract

Over a period of 28 months, 45 episodes of septic shock from 83 episodes of bacteraemia were studied prospectively to evaluate their clinical profile, management and outcome. Thirty-six patients were studied, the overall incidence of septic shock being 54.2%. Gram-negative organisms accounted for 23 (51.1%) of such episodes, Gram-positive 17 (37.8%), and three episodes were polymicrobial (6.7%). The organisms isolated most frequently were Staphylococcus epidermidis (17.8%), Pseudomonas aeruginosa (13.3%), Escherichia coli and Klebsiella sp. (each 11.1%). Coagulation abnormalities were detected in 32 episodes (78%) and disseminated intravascular coagulation (DIC) occurred in 11 of these with high mortality. The most common underlying conditions were respiratory, hepatic and renal failures. The majority of these patients received crystalloids, colloids, vasopressor drugs and blood. Swan-Ganz catheters (SGC) were inserted on eight occasions, the majority of times indicating a hyperdynamic circulatory response. The overall mortality was 40%, despite aggressive management and intensive care. The most important factor in reducing mortality is early detection of bacteraemia and prompt management of these patients.

Entities:  

Mesh:

Year:  1993        PMID: 8473762     DOI: 10.1016/0163-4453(93)92815-e

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  9 in total

Review 1.  Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Manu Shankar-Hari; Gary S Phillips; Mitchell L Levy; Christopher W Seymour; Vincent X Liu; Clifford S Deutschman; Derek C Angus; Gordon D Rubenfeld; Mervyn Singer
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

2.  Detection of cytoplasmic IL-1 beta in peripheral blood mononuclear cells from intensive care unit (ICU) patients.

Authors:  S M Yentis; A W Rowbottom; P G Riches
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

3.  Infections in critically ill patients: experience in MICU at a major teaching hospital.

Authors:  N S Dahmash; S C Arora; D F Fayed; M N Chowdhury
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

4.  Septic shock as a predictor of mortality in bacteremia caused by coagulase-negative staphylococci.

Authors:  A Topeli; S Unal; M Hayran; H E Akalin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-06       Impact factor: 3.267

5.  Expression of Fas and Fas ligand on mouse renal tubular epithelial cells in the generalized shwartzman reaction and its relationship to apoptosis.

Authors:  N Koide; K Narita; Y Kato; T Sugiyama; D Chakravortty; A Morikawa; T Yoshida; T Yokochi
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

6.  Functional characterization of bovine TIRAP and MyD88 in mediating bacterial lipopolysaccharide-induced endothelial NF-kappaB activation and apoptosis.

Authors:  Elizabeth A Cates; Erin E Connor; David M Mosser; Douglas D Bannerman
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2008-08-28       Impact factor: 2.268

7.  DIAGNOSING DISSEMINATED INTRAVASCULAR COAGULATION IN ACUTE INFECTION : CAN WE DO WITHOUT FDP & D-DIMER.

Authors:  M M Arora; K B Mishra; Velu Nair; J R Bhardwaj; Rajvir Bhalwar; B L Somani
Journal:  Med J Armed Forces India       Date:  2011-07-21

8.  Re-evaluation of pneumonia requiring admission to an intensive care unit: a prospective study.

Authors:  N S Dahmash; M N Chowdhury
Journal:  Thorax       Date:  1994-01       Impact factor: 9.139

9.  New Biomarkers for Prediction of Disseminated Intravascular Coagulation in Patients With Sepsis.

Authors:  Ichiro Wakabayashi; Naomi Mambo; Takahiro Ueda; Daisuke Nonaka; Lyang-Ja Lee; Kenji Tanaka; Joji Kotani
Journal:  Clin Appl Thromb Hemost       Date:  2018-10-10       Impact factor: 2.389

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.